Satraplatin for Patients With Metastatic Breast Cancer (MBC)
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT00265655
- Lead Sponsor
- Agennix
- Brief Summary
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
- Detailed Description
This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer.
WHAT IS SATRAPLATIN:
Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine the objective response rate (ORR) of oral satraplatin in patients with metastatic breast cancer 1 year
- Secondary Outcome Measures
Name Time Method In patients with nonmeasurable MBC, to assess the clinical utility of serum CA27.29 (or CA15.3) and circulating tumor cells as predictors of time to disease progression 6 weeks To determine 1-year survival 1 year To determine duration of response 6 weeks To determine progression-free survival (PFS) 1 year To evaluate the toxicities of satraplatin in MBC patients 6 weeks
Trial Locations
- Locations (1)
US Oncology
🇺🇸Dallas, Texas, United States